南アフリカ - 英語 - South African Health Products Regulatory Authority (SAHPRA)

schering -

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

he clissmann - withdrawn form - 1 millilitre

アイルランド - 英語 - HPRA (Health Products Regulatory Authority)

he clissmann - metenolone enantate - 1 millilitre

日本 - 英語 - すりの適正使用協議会 RAD-AR Council, Japan

bayer yakuhin, ltd. - metenolone acetate - white tablet, diameter: 7.0 mm, thickness: 2.7 mm

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

rebel distributors corp - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 400 mg in 40 ml - ciprofloxacin injection, usp is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. please see dosage and administration for specific recommendations. adult patients:   urinary tract infections caused by escherichia coli (including cases with secondary bacteremia), klebsiella pneumoniae subspecies pneumoniae , enterobacter cloacae , serratia marcescens , proteus mirabilis , providencia rettgeri , morganella morganii , citrobacter diversus , citrobacter freundii , pseudomonas aeruginosa , methicillin-susceptible staphylococcus epidermidis , staphylococcus saprophyticus , or enterococcus faecalis . lower respiratory infections caused by escherichia coli , klebsiella pneumoniae subspecies pneumoniae , enterobacter cloacae , proteus mirabilis , pseudomonas aeruginosa , haemophilus

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

rebel distributors corp - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 10 mg in 1 ml - ciprofloxacin injection is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. please see dosage and administration for specific recommendations. urinary tract infections caused by escherichia coli (including cases with secondary bacteremia), klebsiella pneumoniae subspecies pneumoniae, enterobacter cloacae, serratia marcescens, proteus mirabilis, providencia rettgeri, morganella morganii, citrobacter diversus, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus epidermidis, staphylococcus saprophyticus, or enterococcus faecalis. lower respiratory infections caused by escherichia coli, klebsiella pneumoniae subspecies pneumoniae, enterobacter cloacae, proteus mirabilis, pseudomonas aeruginosa, haemophilus influenzae, haemophilus parainfluenzae, or penicillin-suscepti

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hospira, inc. - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 2 mg in 1 ml - ciprofloxacin injection (in 5% dextrose injection) is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin injection (in 5% dextrose injection) is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin injection (in 5% dextrose injection) is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin injection (in 5% dextrose injection) is ind

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

sagent pharmaceuticals - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin 2 mg in 1 ml - ciprofloxacin injection (in 5% dextrose injection) is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin injection is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa . ciprofloxacin injection is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis . ciprofloxacin injection is indicated in adult patients for treatment of nosocomial pneumonia caused by haemop

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

hospira, inc. - ciprofloxacin (unii: 5e8k9i0o4u) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin injection (in 5% dextrose injection) is indicated in adult patients for treatment of skin and skin structure infections caused by escherichia coli, klebsiella pneumoniae, enterobacter cloacae, proteus mirabilis, proteus vulgaris, providencia stuartii, morganella morganii, citrobacter freundii, pseudomonas aeruginosa, methicillin-susceptible staphylococcus aureus, methicillin-susceptible staphylococcus epidermidis, or streptococcus pyogenes. ciprofloxacin injection (in 5% dextrose injection) is indicated in adult patients for treatment of bone and joint infections caused by enterobacter cloacae, serratia marcescens, or pseudomonas aeruginosa. ciprofloxacin injection (in 5% dextrose injection) is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by escherichia coli, pseudomonas aeruginosa, proteus mirabilis, klebsiella pneumoniae, or bacteroides fragilis. ciprofloxacin injection (in 5% dextrose injection) is ind